Back to Search
Start Over
791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)
- Source :
- Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
- Publication Year :
- 2020
- Publisher :
- BMJ Publishing Group, 2020.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 8
- Issue :
- Suppl 3
- Database :
- Directory of Open Access Journals
- Journal :
- Journal for ImmunoTherapy of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.1bb5d961b34043bcb896460e4288e20f
- Document Type :
- article
- Full Text :
- https://doi.org/10.1136/jitc-2020-SITC2020.0791